GLP-1 Drugs Such as Ozempic and Wegovy May Reduce Depression and Anxiety Risks, Study Finds

New research indicates that GLP-1 receptor agonists, a class of medications including Ozempic, Wegovy, and other diabetes and weight-loss drugs, may offer benefits beyond metabolic health by reducing the risk of worsening depression and anxiety.

The findings, published in the April 2024 issue of The Lancet Psychiatry, suggest these drugs could provide a dual advantage for patients managing both metabolic and mental health conditions. However, experts emphasize that further clinical trials are necessary before GLP-1s can be recommended as a primary treatment for mental health disorders.

Study Details and Key Findings

The research analyzed health data from 95,490 individuals in Sweden diagnosed with depression, anxiety, or both, and prescribed diabetes medications between 2009 and 2022. The study focused on four GLP-1 receptor agonists:

• Semaglutide (Wegovy, Ozempic, Rybelsus)
• Liraglutide (Saxenda)
• Exenatide (Byetta, Bydureon BCise)
• Dulaglutide (Trulicity)

Researchers compared periods when participants were taking these medications to periods when they were not, using a within-individual design. This approach minimized the influence of variables such as age, gender, or overall health that remain constant over time.

Data Collection and Outcomes

Data were sourced from national electronic health registers, including:

• Hospital admissions
• Sick leave records
• Death registries

The primary outcome measured was a composite of:

• Psychiatric hospitalizations
• Extended sick leave for psychiatric reasons
• Hospitalization due to self-harm
• Death by suicide

Secondary outcomes included:

• Worsening of depression or anxiety
• Substance use disorders
• Self-harm incidents

The study also compared GLP-1 receptor agonists with other second-line diabetes medications, such as:

• Empagliflozin (Jardiance)
• Dapagliflozin (Farxiga)
• Sitagliptin (Januvia)

Statistical models adjusted for time-varying factors, including the order and duration of medication use, as well as concurrent treatment with psychiatric or antidiabetic drugs. This adjustment aimed to isolate the effects of GLP-1 receptor agonists on mental health within the observational data.

Results: Reduced Hospitalizations and Sick Leave

Over an average follow-up period of 5.2 years, approximately 23.5% of the cohort used GLP-1 receptor agonists, with semaglutide and liraglutide being the most commonly prescribed. The study found that these medications were associated with a lower risk of worsening mental health outcomes, including:

• Fewer psychiatric hospitalizations
• Reduced sick leave due to mental health reasons
• Lower incidence of self-harm and suicide-related events

Potential Mechanisms Behind the Benefits

Experts hypothesize that the positive effects of GLP-1 drugs on mental health may stem from their influence on dopamine signaling and brain inflammation. These mechanisms could contribute to improved mood regulation and reduced symptoms of depression and anxiety. However, the exact pathways remain under investigation.

Researchers also noted that individuals living with diabetes often face an elevated risk of developing mental health conditions. The study’s findings suggest that GLP-1 receptor agonists may help mitigate this risk, offering a potential dual benefit for patients.

Expert Caution: Further Research Needed

While the results are promising, the researchers stress that additional clinical trials are required to confirm the efficacy of GLP-1 drugs in treating mental health disorders. The current study is observational, meaning it cannot establish causality. Randomized controlled trials are necessary to validate these findings and determine the optimal use of GLP-1 receptor agonists for mental health management.

The study’s authors conclude that GLP-1 receptor agonists represent a potential avenue for addressing both metabolic and mental health challenges, but more rigorous research is needed before clinical recommendations can be made.